Which feature best distinguishes ciprofloxacin from levofloxacin among fluoroquinolones?

Explanation

## Distinguishing Ciprofloxacin from Levofloxacin ### Generation and Spectrum Evolution **Key Point:** Levofloxacin (second-generation) represents an evolutionary improvement over ciprofloxacin (first-generation) with enhanced gram-positive and atypical coverage. | Feature | Ciprofloxacin | Levofloxacin | |---------|---------------|---------------| | **Generation** | First | Second | | **Gram-positive activity** | Weak | Superior | | **Atypical organisms** | Moderate | Excellent (Legionella, Mycoplasma) | | **Gram-negative activity** | Excellent | Excellent | | **Pseudomonas coverage** | Best among FQs | Good but less than cipro | | **Isomer form** | Racemic mixture | L-isomer (active form) | | **Half-life** | 4 hours | 6–8 hours | | **Dosing** | Twice daily | Once daily | ### Clinical Implications **High-Yield:** Levofloxacin's superior gram-positive and atypical organism coverage makes it the preferred choice for respiratory infections (community-acquired pneumonia, atypical pneumonia), whereas ciprofloxacin remains the gold standard for gram-negative and Pseudomonas aeruginosa infections (UTIs, GI infections, cystic fibrosis). **Clinical Pearl:** Levofloxacin is the L-isomer (the pharmacologically active enantiomer), not a racemic mixture. Ciprofloxacin is the racemic mixture, which is why levofloxacin achieves higher serum concentrations at lower doses. ### Why Levofloxacin Is Superior for Atypicals 1. Better intracellular penetration (especially into macrophages) 2. Higher lung tissue concentrations 3. Enhanced activity against Legionella pneumophila and Mycoplasma pneumoniae **Mnemonic:** **LAMP** — Levofloxacin for Atypicals, Mycoplasma, Pneumonia (respiratory infections).